Natco Pharma Ltd has announced a tie-up with USA based Akorn, Inc. for API supply and margin sharing to commercialize two ANDA injectable drug products.

The two ANDA drug products will focus on the anti-emetic and cancer related markets, and have a combined current market size of approximately $ 875 million. Under the API supply and margin sharing agreement, the company will be responsible for the supply of active pharmaceutical ingredients for both drug products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home healthcare markets in the United States and Canada.

Chowdary V Nannapaneni, chairman and managing director stated, "This arrangement helps in bringing down development expense and compete with vertically integrated firms in a competitive generic business".